Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes

Ruta Maniusyte, Angharad Pryce, Rachel Pearce, John A Snowden, Ram Malladi, Victoria Potter, Julia Lee, Marie Wilson, Antonio Pagliuca, Eduardo Olavarria, Renuka Palanicawandar, Chloe Anthias, Rachel Pawson, Robert David Danby

Blood (2022) 140 (Supplement 1): 7552–7554.

https://doi.org/10.1182/blood-2022-163039

Published: 2022

Journal Articles

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Marcos de Lima, Florent Malard, Eduardo Olavarria, Estefanía Pérez López, Michael Medinger, Elisabeth Kueenburg, Malika Souquieres, Julien Cachat, Christos Stylianou, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 12936–12937.

https://doi.org/10.1182/blood-2022-159785

Published: 2022

Journal Articles

Total Body Irradiation Is Associated with Higher Prevalence of Cerebral Microbleeds in Haematopoietic Stem Cell Transplant Survivors

Jure Hederih, Asad Charania, Adam Waldman, Jiri Pavlu, Richard Szydlo, Dragana Milojkovic, Eduardo Olavarria, Renuka Palanicawandar, Camelia Vladescu, Jose Ros Soto, Andrew J. Innes, Nichola Cooper

Blood (2022) 140 (Supplement 1): 12910–12912.

https://doi.org/10.1182/blood-2022-168057

Published: 2022

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Steven Devine, Stephan Mielke, MD, Eduardo Olavarria, Bert Tuk, Kees Meewisse, Andrew Sandler, MD, Denis-Claude Roy, MD

Blood (2018) 132 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2018-99-118857

Published: 2018

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

Andrew James Innes, PhD FRCPath, MRCP, Philippa Woolley, MRCP, MBBS, Richard Szydlo, PhD, Sara Lozano, Fiona Fernando, MBChB, Divya Bansal, Renuka Palanicawandar, MD MRCP,FRCPath, Elisabet Nadal-Melsio, MD, Eva Yebra-Fernandez, MD, Jane Apperley, MB ChB MD, Eduardo Olavarria, MD PhD, Jiri Pavlu, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2018-99-117311

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Jean-Sebastien Delisle, MD PhD, Stephen Ronan Foley, MD, Philippe Lewalle, MDPhD, Eduardo Olavarria, Dominik Selleslag, MD, Manfred Rüdiger, PhD, Jurjen Velthuis, PhD, Lisya Gerez, Jeroen Rovers, MD PhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2016) 128 (22): 1226.

https://doi.org/10.1182/blood.V128.22.1226.1226

Published: 2016

Journal Articles

Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia

Philippa J Rohman, Richard M Szydlo, Emily Hobbs, Renuka Palanicawandar, Belen Sevillano, Silvia Monsalvo, Andrew Innes, Edward J Kanfer, Dragana Milojkovic, Ian H Gabriel, Christian Jakob, Donald Macdonald, Aristeidis Chaidos, Anastasios Karadimitris, Jane F Apperley, Eduardo Olavarria, Jiří Pavlů

Blood (2016) 128 (22): 3411.

https://doi.org/10.1182/blood.V128.22.3411.3411

Published: 2016

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience

Daniele Avenoso, Anne Bradshaw, Andrew Innes, Josu de la Fuente, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 5741.

https://doi.org/10.1182/blood.V128.22.5741.5741

Published: 2016

Journal Articles

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

Oscar M. Pello, Anne Bradshaw, Andrew Innes, Sally-Anne Finn, Emma Bray, Shab Uddin, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 5726.

https://doi.org/10.1182/blood.V128.22.5726.5726

Published: 2016

Journal Articles

Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT

Blood (2016) 128 (22): 4685.

https://doi.org/10.1182/blood.V128.22.4685.4685

Published: 2016

Journal Articles

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Julie Beckerson, Richard M Szydlo, Mary Hickson, Catriona E Mactier, Andrew Innes, Ian H Gabriel, Renuka Palanicawandar, Edward J Kanfer, Donald Macdonald, Dragana Milojkovic, Amin Rahemtulla, Aristeidis Chaidos, Anastasios Karadimitris, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 2226.

https://doi.org/10.1182/blood.V128.22.2226.2226

Published: 2016

Journal Articles

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

Blood (2016) 128 (22): 628.

https://doi.org/10.1182/blood.V128.22.628.628

Published: 2016

Journal Articles

Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party

Kavita Raj, MD PhD, Eduardo Olavarria, Diderik-Jan Eikema, Liesbeth C de Wreede, PhD, Linda Koster, Maria Teresa van Lint, Fabio Ciceri, MD, Jakob Passweg, MD, Nicolaas PM Schaap, MD PhD, Kristina Carlson, MD PhD, Didier Blaise, MD PhD, Stella Santarone, MD, Antonin Vitek, MD PhD, Jose L. Diez-Martin, MD PhD, Donal McLornan, MB, Bch (Hons), PhD MRCP, FRCPath, Marie Robin, MD PhD, Yves Chalandon, MD, Nicolaus Kroeger, MD

Blood (2016) 128 (22): 4655.

https://doi.org/10.1182/blood.V128.22.4655.4655

Published: 2016

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Blood (2015) 126 (23): 4403.

https://doi.org/10.1182/blood.V126.23.4403.4403

Published: 2015

NARROW

Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Total Body Irradiation Is Associated with Higher Prevalence of Cerebral Microbleeds in Haematopoietic Stem Cell Transplant Survivors

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only